- Home
- GBIO vs FCCO Comparison
GBIO vs FCCO Comparison
Compare GBIO & FCCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- FCCO
- Stock Information
- Founded
- GBIO 2016
- FCCO 1994
- Country
- GBIO United States
- FCCO United States
- Employees
- GBIO N/A
- FCCO N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- FCCO Major Banks
- Sector
- GBIO Health Care
- FCCO Finance
- Exchange
- GBIO Nasdaq
- FCCO Nasdaq
- Market Cap
- GBIO 64.8M
- FCCO N/A
- IPO Year
- GBIO 2020
- FCCO 1998
- Fundamental
- Price
- GBIO $0.88
- FCCO $22.97
- Analyst Decision
- GBIO Strong Buy
- FCCO Buy
- Analyst Count
- GBIO 2
- FCCO 1
- Target Price
- GBIO $6.50
- FCCO $21.00
- AVG Volume (30 Days)
- GBIO 581.0K
- FCCO 31.8K
- Earning Date
- GBIO 03-05-2025
- FCCO 01-22-2025
- Dividend Yield
- GBIO N/A
- FCCO 2.63%
- EPS Growth
- GBIO N/A
- FCCO 2.46
- EPS
- GBIO N/A
- FCCO 1.69
- Revenue
- GBIO $18,582,000.00
- FCCO $62,732,000.00
- Revenue This Year
- GBIO $212.74
- FCCO N/A
- Revenue Next Year
- GBIO N/A
- FCCO $11.21
- P/E Ratio
- GBIO N/A
- FCCO $13.19
- Revenue Growth
- GBIO 514.08
- FCCO 6.16
- 52 Week Low
- GBIO $0.75
- FCCO $15.40
- 52 Week High
- GBIO $4.65
- FCCO $26.48
- Technical
- Relative Strength Index (RSI)
- GBIO 28.66
- FCCO 35.98
- Support Level
- GBIO $0.85
- FCCO $22.11
- Resistance Level
- GBIO $1.01
- FCCO $24.07
- Average True Range (ATR)
- GBIO 0.12
- FCCO 0.45
- MACD
- GBIO 0.00
- FCCO -0.18
- Stochastic Oscillator
- GBIO 7.50
- FCCO 36.29
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.